Bristol-Myers Squibb Canada Co. v. Pharmascience Inc. re: ELIQUIS®

Represented Bristol-Myers Squibb in a successful patent infringement action brought under the Patented Medicines (Notice of Compliance) Regulations in relation to the drug ELIQUIS® in which BMS's patents were held to be valid and infringed at trial and on appeal.